Drug shortage: Sodium Bicarbonate Injection (SODIUM BICARBONATE)
FDA lists 15 presentations as Current. Availability: Unavailable (1), Limited Availability (3), Available (7). Reason: Other; Demand increase for the drug. Companies: Exela Pharma Sciences, LLC, Hospira, Inc., a Pfizer Company, Fresenius Kabi USA, LLC, Long Grove Pharmaceuticals LLC, Amphastar Pharmaceuticals, Inc..
- Published by source
- 2017-03-01
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Exela Pharma Sciences, LLC
- Products
- Sodium Bicarbonate Injection SODIUM BICARBONATE
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: Current — Unavailable
Remedy / actions:
- Discontinuation of the manufacture of the drug
- Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2017-03-01
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #915 | new | 2026-10-22 | 0be21d197d1f…a4702f | b61a5b8b3a58…6bef88 |
Chain head: #1094 edf3be25ec2e…478842